We List Some of the Legal Liability Allegations Regarding Drug Company Actions and Failures
(Posted by Tom Lamb at Drug Injury Watch)
During the past several weeks, Ozempic vision loss lawsuits have been filed by patients against
Law Offices of Thomas J. Lamb, P.A.
Website:
https://www.drug-injury.com/
Law Offices of Thomas J. Lamb, P.A. Blogs
Blog Authors
Latest from Law Offices of Thomas J. Lamb, P.A.
March 2025 Medical Article About Blindness or Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients
By Tom Lamb
Discusses Timing for Increased Risk of Semaglutide-related Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) Side Effect
(Posted by Tom Lamb at Drug Injury Watch)
On March 27, 2025, the JAMA Ophthalmology medical journal published a report about a…
Ozempic Vision Problems From Semaglutide Apply to Wegovy and Rybelsus, Also
By Tom Lamb
NAION Eye Side Effect Risk Increased With Semaglutide Drugs – Two Recent Medical Studies
(Posted by Tom Lamb at Drug Injury Watch)
Two recent medical studies again link the eye side effect of non-arteritic anterior ischemic optic…
Meningioma Warning For Depo-Provera Recommended in Europe by Drug Regulator
By Tom Lamb
Why Has This September 2024 European Medicines Agency (EMA) Action Not Been Followed by FDA in US?
(Posted by Tom Lamb at Drug Injury Watch)
One of the primary issues in the increasing number of Depo-Provera meningioma…
Depo-Provera Drug Label Warnings in US Do Not Include Increased Risk of Intracranial Meningioma
By Tom Lamb
While European Union (EU) and United Kingdom (UK) Drug Labels Have Warned About Meningioma for Many Years
(Posted by Tom Lamb at Drug Injury Watch)
Drug injury lawsuits that involve the contraceptive injection Depo-Provera being linked to…
Possible Andexxa Recall After FDA Does Not Approve the Anticoagulant Reversal Drug in December 2024
By Tom Lamb
AstraZeneca Says “while discussions with the FDA are ongoing, Andexxa will remain on the US market.”
(Posted by Tom Lamb at Drug Injury Watch)
In our November 21, 2024 article, “Do Andexxa Risks Outweigh Benefits Given…
Semaglutide Weight-Loss Drugs Like Ozempic Linked to Vision Loss: December 2024 Update
By Tom Lamb
European Drug Regulators Investigating Semaglutide-Related NAION Cases Presented in Two Danish Studies
(Posted by Tom Lamb at Drug Injury Watch)
According to this December 18, 2024, Reuters news report, “Novo Nordisk’s Ozempic faces EU review for…
Updated Ocaliva Liver Injury Warnings Are Issued By The FDA In December 2024
By Tom Lamb
New Cases of Liver Transplants And Liver-Related Deaths Among Patients Who Did Not Have Cirrhosis
(Posted by Tom Lamb at Drug Injury Watch)
In a December 12, 2024, Drug Safety Communication the FDA said it had recently…
Do Andexxa Risks Outweigh Benefits Given Increased Rate of Thrombosis and Thrombosis-Related Deaths?
By Tom Lamb
Issue to be Considered by FDA Advisory Committee on November 21, 2024, and Discussion May Lead to Andexxa Drug Recall
(Posted by Tom Lamb at Drug Injury Watch)
At its November 21, 2024 meeting, the FDA’s Cellular,…
Side Effects of Birth Control: Brain Tumors Related to Depo-Provera Contraceptive Injections
By Tom Lamb
Intracranial Meningioma Risks Are Increased When Depo-Provera Was Used for More Than One Year
(Posted by Tom Lamb at Drug Injury Watch)
A medical journal article published in March 2024 reported that Depo-Provera (medroxyprogesterone acetate) increased the…